Favorable mortality and heart failure hospitalization rates, along with improved functional status, observed among recipients of LuX-Valve device for severe symptomatic tricuspid regurgitation.

Key findings reported in the year include: Cardiovalve TARGET CE Pivotal Study (Europe) Immediate outcomes in the first 105 patients demonstrated 93.7% achieved ≤mild tricuspid regurgitation.

Cardiovalve's trial in the treatment of tricuspid regurgitation enrolled nearly 120 patients across 30+ renowned cardiovascular centers in Germany, Italy, Spain, the UK, and Canada. The Company ...